Long Scientific

Long Scientific is a specialty pharmaceutical company focused on developing long-acting injectable (LAI) formulations of established therapeutic agents. Utilizing its proprietary drug delivery platform, the company aims to improve patient compliance and therapeutic outcomes in chronic conditions such as schizophrenia and ophthalmological diseases. Their lead programs, LS-101 and LS-102, are extended-release versions of antipsychotics designed to provide multi-month dosing intervals. The company primarily utilizes the 505(b)(2) regulatory pathway to accelerate development and reduce clinical risk. Long Scientific is headquartered in San Diego, California, and continues to expand its pipeline into oncology and other therapeutic areas requiring sustained drug release.